20087176

Source:http://linkedlifedata.com/resource/pubmed/id/20087176

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0027022, umls-concept:C1152564, umls-concept:C1334291
pubmed:issue	2
pubmed:dateCreated	2010-2-10
pubmed:abstractText	The pathophysiology of Philadelphia-chromosome negative myeloproliferative disorders has significantly advanced with the discovery of JAK2V617F. The prevalence of JAK2V617F mutation has made it a much anticipated target for inhibition; this review will update and assess progress.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/9430802
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Janus Kinase 2, http://linkedlifedata.com/resource/pubmed/chemical/Protein Kinase Inhibitors
pubmed:status	MEDLINE
pubmed:month	Mar
pubmed:issn	1531-7048
pubmed:author	pubmed-author:ChenAndrew TAT, pubmed-author:PrchalJosef TJT
pubmed:issnType	Electronic
pubmed:volume	17
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	110-6
pubmed:meshHeading	pubmed-meshheading:20087176-Humans, pubmed-meshheading:20087176-Janus Kinase 2, pubmed-meshheading:20087176-Myeloproliferative Disorders, pubmed-meshheading:20087176-Protein Kinase Inhibitors
pubmed:year	2010
pubmed:articleTitle	JAK2 kinase inhibitors and myeloproliferative disorders.
pubmed:affiliation	Hematology and Medical Oncology, University of Utah, Salt Lake City, Utah, USA.
pubmed:publicationType	Journal Article, Review